Status:
COMPLETED
The Association of Affective Resonance With Empathy Modulated by Negative Symptomatology and Oxytocin
Lead Sponsor:
Charite University, Berlin, Germany
Conditions:
Schizophrenia Spectrum Disorders
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
In previous studies the neuropeptide oxytocin has been in particular associated with social enhancing and anxiety relieving effects. The purpose of this study is to investigate the effect of oxytocin...
Detailed Description
The study design is based on an experimental, double-blinded (participants, instructor), placebo-controlled, proof-of-concept randomized, trial and complies with the CONSORT guidelines. The study was ...
Eligibility Criteria
Inclusion
- Informed consent
- Psychiatric diagnosis from the schizophrenic spectrum (ICD-10: F2x.x spectrum) for group of patients
- Mild to moderate positive symptoms (5 \< positive symptoms on individual items using P-PANSS)
- Age: 18 - 65 years
- German should either be the mother tongue or spoken at a native level.
Exclusion
- Acute psychotic episode with severe positive symptoms (ICD-10: F2 spectrum, 5 ≥ positive symptoms on individual items using P-PANSS).
- Acute suicidality
- Acute consumption phase of a substance dependence, except nicotine
- No severe physical impairments, neurological diseases and e.g. severe craniocerebral trauma e.g. early childhood brain damage
Key Trial Info
Start Date :
August 2 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 30 2022
Estimated Enrollment :
41 Patients enrolled
Trial Details
Trial ID
NCT05247151
Start Date
August 2 2021
End Date
January 30 2022
Last Update
February 18 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Charité Universitätsmedizin Berlin, Campus Benjamin Franklin
Berlin, Germany, 12203